Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

https://eternatx.com

• YTD Return

  ERNA-65.85%
  S&P 500+24.05%

• 1-Year Return

  ERNA-45.60%
  S&P 500+31.08%

• 3-Year Return

  ERNA-99.55%
  S&P 500+25.95%

• 5-Year Return

  ERNA-99.41%
  S&P 500+89.64%